ANI Pharmaceuticals, Inc. (ANIP): Price and Financial Metrics


ANI Pharmaceuticals, Inc. (ANIP): $33.09

-0.53 (-1.58%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ANIP to Watchlist
Sign Up

Industry: Biotech


Ranked

of 486

in industry

ANIP POWR Grades


  • Growth is the dimension where ANIP ranks best; there it ranks ahead of 96.03% of US stocks.
  • The strongest trend for ANIP is in Momentum, which has been heading down over the past 31 weeks.
  • ANIP's current lowest rank is in the Momentum metric (where it is better than 11.83% of US stocks).

ANIP Stock Summary

  • Of note is the ratio of Ani Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; 28.38% of US stocks have a lower such ratio.
  • Over the past twelve months, ANIP has reported earnings growth of -252.97%, putting it ahead of only 8.37% of US stocks in our set.
  • In terms of volatility of its share price, ANIP is more volatile than only 13.96% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Ani Pharmaceuticals Inc, a group of peers worth examining would be ESTE, HAYN, MBII, STIM, and PWFL.
  • Visit ANIP's SEC page to see the company's official filings. To visit the company's web site, go to www.anipharmaceuticals.com.

ANIP Price Target

For more insight on analysts targets of ANIP, see our ANIP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $38.33 Average Broker Recommendation 1.5 (Moderate Buy)

ANIP Stock Price Chart Interactive Chart >

Price chart for ANIP

ANIP Price/Volume Stats

Current price $33.09 52-week high $40.00
Prev. close $33.62 52-week low $23.55
Day low $33.09 Volume 273
Day high $33.46 Avg. volume 56,975
50-day MA $34.26 Dividend yield N/A
200-day MA $30.98 Market Cap 409.16M

ANI Pharmaceuticals, Inc. (ANIP) Company Bio


ANI Pharmaceuticals is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The company was founded in 2004 and is based in Baudette, Minnesota.


ANIP Latest News Stream


Event/Time News Detail
Loading, please wait...

ANIP Latest Social Stream


Loading social stream, please wait...

View Full ANIP Social Stream

Latest ANIP News From Around the Web

Below are the latest news stories about Ani Pharmaceuticals Inc that investors may wish to consider to help them evaluate ANIP as an investment opportunity.

ANI Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference 2021

BAUDETTE, Minn., Jun 15, 2021--ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Raymond James Human Health Innovation Conference 2021 as follows:

Yahoo | June 15, 2021

ANI Pharmaceuticals Reports First Quarter 2021 Results - BioSpace

ANI Pharmaceuticals Reports First Quarter 2021 Results BioSpace

BioSpace | June 2, 2021

ANI Pharmaceuticals Announces Details of 2021 Virtual Annual Meeting of Stockholders

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced log-in details for its 2021 Virtual Annual Meeting of Stockholders to be held on June 2, 2021, beginning at 10 a.m. Eastern Time.

BioSpace | May 31, 2021

ANI Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Jefferies Virtual Healthcare Conference 2021 as follows: Date: Friday, June 4, 2021 Time: 10:00 a.m. ET

BioSpace | May 26, 2021

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System trimmed its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 2.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 23,180 shares of the specialty pharmaceutical companys stock after selling 700 shares during the period. New []

Dakota Financial News | May 12, 2021

Read More 'ANIP' Stories Here

ANIP Price Returns

1-mo -6.47%
3-mo 6.50%
6-mo 18.18%
1-year 8.24%
3-year -51.40%
5-year -41.19%
YTD 13.95%
2020 -52.91%
2019 36.98%
2018 -30.15%
2017 6.32%
2016 34.32%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.1706 seconds.